EUVIMEDEUVIMED entdecken
Open Access

Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group

Karen M Chisholm iD, Jenny Smith, Amy E Heerema-McKenney, John K Choi iD, Rhonda E Ries, Betsy A Hirsch, Susana C Raimondi, Yi-Cheng Wang, Alice Dang, Todd A Alonzo, Lillian Sung, Richard Aplenc und 3 weitere

Pediatric Blood & Cancer · 2023-05 · 70 (5)

DOI: 10.1002/pbc.30251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 15.02.2023. Verfasst von Karen M Chisholm und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, St. Baldrick's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) with megakaryocytic differentiation (AMkL) is a rare subtype of AML more common in children. Recent literature has identified multiple fusions associated with this type of leukemia.

Methods

Morphology, cytogenetics, and genomic sequencing were assessed in patients from Children's Oncology Group trials AAML0531 and AAML1031 with central‐pathology review confirmed non‐Down syndrome AMkL. The 5‐year event‐free survival (EFS), overall survival (OS), and RR were evaluated in these AMkL subcategories.

Results

A total of 107 cases of AMkL (5.5%) were included. Distinct fusions were identified in the majority: RBM15::MRTFA (20%), CBFA2T3::GLIS2 (16%), NUP98 (10%), KMT2A (7%), TEC::MLLT10 (2%), MECOM (1%), and FUS::ERG (1%); many of the remaining cases were classified as AMkL with (other) myelodysplasia‐related changes (MRC). Very few cases had AML‐associated somatic mutations. Cases with CBFA2T3::GLIS2 were enriched in trisomy 3 ( p = .015) and the RAM phenotype, with associated high CD56 expression ( p < .001). Cases with NUP98 fusions were enriched in trisomy 6 ( p < .001), monosomy 13/del(13q) ( p < .001), trisomy 21 ( p = .026), and/or complex karyotypes ( p = .026). While different 5‐year EFS and OS were observed in AMkL in each trial, in general, those with CBFA2T3::GLIS2 or KMT2A rearrangements had worse outcomes compared to other AMkL, while those with RBM15::MRTFA or classified as AMkl‐MRC fared better. AMkL with NUP98 fusions also had poor outcomes in the AAML1031 trial.

Conclusion

Given the differences in outcomes, AMkL classification by fusions, cytogenetics, and morphology may be warranted to help in risk stratification and therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAdolescentChildChild, PreschoolFemaleHumansInfantMaleYoung AdultCytogenetic AnalysisDisease-Free SurvivalDown SyndromeGene FusionMutation Rate

Stichwörter der Autor:innen

CBFA2T3::GLIS2NUP98 fusionsacute megakaryoblastic leukemiaacute myeloid leukemiapediatric acute myeloid leukemia

Autor:innen und Institutionen

  • Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Division of Laboratory Medicine, University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, USA.

ORCID-Profile: Karen M Chisholm, John K Choi

Förderung

  • NCI NIH HHS
  • St. Baldrick's Foundation

Zitieren

APA

Chisholm, K. M., Smith, J., Heerema-McKenney, A. E., Choi, J. K., Ries, R. E., Hirsch, B. A., Raimondi, S. C., Wang, Y. C., Dang, A., Alonzo, T. A., Sung, L., Aplenc, R., Gamis, A. S., Meshinchi, S., & Kahwash, S. B. (2023). Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. Pediatric Blood & Cancer, 70(5). https://doi.org/10.1002/pbc.30251

Vancouver

Chisholm KM, Smith J, Heerema-McKenney AE, Choi JK, Ries RE, Hirsch BA, et al. Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 2023;70(5). doi:10.1002/pbc.30251

BibTeX
@article{Chisholm2023,
  author = {Chisholm, Karen M and Smith, Jenny and Heerema-McKenney, Amy E and Choi, John K and Ries, Rhonda E and Hirsch, Betsy A and Raimondi, Susana C and Wang, Yi-Cheng and Dang, Alice and Alonzo, Todd A and Sung, Lillian and Aplenc, Richard and Gamis, Alan S and Meshinchi, Soheil and Kahwash, Samir B},
  title = {Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  volume = {70},
  number = {5},
  doi = {10.1002/pbc.30251}
}
Kostenlos starten →